A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa

Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin 17A, to which it binds with high affinity. This study investigates izokibep in participants with active Hidradenitis Suppurativa (HS), including tumor necrosis factor-alpha inhibitor (TNFi) naïve participants, and those who had an inadequate response or intolerance to TNFi, or for whom TNFi is contraindicated.

开始日期2023-06-22

申办/合作机构

ACELYRIN, Inc.

NCT05623345

/ Terminated临床2/3期

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Active Psoriatic Arthritis

Izokibep is a potent and selective inhibitor of interleukin (IL)-17A that is being developed for treatment of psoriatic arthritis (PsA).
This study will evaluate the efficacy of izokibep in subjects with PsA.

开始日期2022-11-21

申办/合作机构

ACELYRIN, Inc.

NCT05384249

/ Terminated临床2期

A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Non-infectious, Intermediate-, Posterior- or Pan-uveitis

Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin-17A, to which it binds with high affinity. This study investigates izokibep in subjects with active non-infectious, intermediate-, posterior- or pan-uveitis requiring high-dose steroids.

开始日期2022-08-23

申办/合作机构

ACELYRIN, Inc.

100 项与 Izokibep 相关的临床结果

登录后查看更多信息

100 项与 Izokibep 相关的转化医学

登录后查看更多信息

100 项与 Izokibep 相关的专利（医药）

登录后查看更多信息

项与 Izokibep 相关的文献（医药）

2026-03-01·Mediterranean journal of rheumatology

The Pathophysiological Significance of Dual Inhibition of IL-17A and IL-17F in Psoriatic Arthritis and Axial Spondyloarthritis

Review

作者: Lainis, Vasileios ; Vlachoyiannopoulos, Panayiotis G ; Goules, Andreas V ; Katsouli, Olga

Objective:

Spondylarthritides (SpA), including psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are immune-mediated diseases in which the IL-23/IL-17 axis plays a central role. IL-17A inhibition is already a well-established and effective treatment strategy. Emerging evidence suggests that IL-17F, a cytokine closely related to IL-17A but less potent, is not a passive bystander but a key participant in chronic sustained inflammation and therapeutic escape, offering a compelling concept for dual inhibition. This review aims to examine the pathophysiological significance of dual inhibition of IL-17A and IL-17F in psoriatic arthritis and axial spondyloarthritis.

Methods:

Conducting a search through PubMed/MEDLINE, Scopus, and Web of Science, using keywords and Medical Subject Headings (MeSH) terms such as "spondyloarthritis", "psoriatic arthritis", "IL-17A", "IL-17F", "IL-23", "IL-23 independent mechanisms", "dual inhibition", "pathogenesis", "gut-joint axis", "secukinumab", "ixekizumab", "bimekizumab", "sonelokimab", we select the relevant literature for this comprehensive pathophysiological narrative.

Results:

This review examines the distinct and synergistic functions of IL-17A and IL-17F in key tissues, including the synovium, enthesis, skin, gut, and eye, and their contribution to the paradoxical imbalance of bone remodelling. The advent of dual IL-17A/F inhibitors, particularly bimekizumab has revolutionised our therapeutic approach, offering a promising option for patients with difficult-to-treat SpA. We also discuss emerging technology agents, such as sonelokimab and izokibep.

Conclusion:

Inhibiting both IL-17A and IL-17F signifies not only a significant therapeutic advancement but also a vital strategy towards overcoming the limitations of our current armamentarium in achieving deeper and more sustained remission in SpA. Future studies and long-term data will be essential in determining the position of dual IL-17A/F inhibitors within treatment guidelines.

2025-06-01·ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Article

作者: Wiens, Brian ; Brandt-Juergens, Jan ; Feldwisch, Joachim ; Dokoupilova, Eva ; Drescher, Edit ; Mpofu, Shephard ; Brun, Nikolai C ; Abdel-Kader Martin, Nadia ; Mease, Philip J ; Behrens, Frank ; Ohlman, Sven ; Taylor, Peter C ; Koskinen, Lisa Osterling ; Wetzel, Dieter ; de Vlam, Kurt ; Rowińska-Osuch, Anna ; Stevens, Anne M ; Frejd, Fredrik Y

OBJECTIVES:

To evaluate the efficacy and safety of izokibep, a small protein therapeutic designed to inhibit interleukin-17A, in patients with active psoriatic arthritis (PsA) over 46 weeks.

METHODS:

This phase 2, multicentre, placebo-controlled study randomised adult patients with active PsA 1:1:1 to izokibep 40 mg, izokibep 80 mg, or placebo every 2 weeks for 16 weeks; subsequently, placebo-treated patients switched to izokibep 80 mg. The primary end point was American College of Rheumatology criteria 50 (ACR50) at week 16 for izokibep 80 mg vs placebo. Additional efficacy end points and treatment-emergent adverse events were evaluated through week 16 (placebo-controlled) and week 46.

RESULTS:

Of 172 patients screened, 135 were randomised to izokibep 40 mg (n = 44), izokibep 80 mg (n = 47), or placebo (n = 44). ACR50 response rates were significantly higher for izokibep 80 mg vs placebo at week 16 (52% vs 13%; 2-sided P = .0006) and week 12 (50% vs 6%; P < .0001); lower rates were observed for izokibep 40 mg (48% and 43% for weeks 16 and 12, respectively). Additional analyses of arthritis, psoriasis, enthesitis, dactylitis, and quality of life outcomes supported the efficacy of izokibep at both doses. Response rates generally continued to increase through week 46 with izokibep 80 mg. Treatment-emergent adverse event rates were generally similar across treatment groups except for injection site reactions.

CONCLUSIONS:

Izokibep resulted in significant and clinically meaningful improvements over placebo across multiple disease domains, and the originally randomised 80-mg dose showed continued improvements to week 46. There were no unexpected safety risks identified. Izokibep's small size and high potency have the potential for further improved disease control, justifying additional investigation of higher doses.

2025-06-01·CYTOKINE & GROWTH FACTOR REVIEWS

Interleukin-17: A pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders

Review

作者: Kurzrock, Razelle ; Lippman, Scott M ; Nishizaki, Daisuke ; Kato, Shumei ; Saran, Anushka

IL-17A, referred to as IL-17, is the founding member of a family of pro-inflammatory cytokines, including IL-17B, IL-17C, IL-17D, IL-17E (or IL-25), and IL-17F, which act via receptors IL-17RA to IL-17RE, and elicit potent cellular responses that impact diverse diseases. IL-17's interactions with various cytokines include forming a heterodimer with IL-17F and being stimulated by IL-23's activation of Th17 cells, which can lead to inflammation and autoimmunity. IL-17 is implicated in infectious diseases and inflammatory disorders such as rheumatoid arthritis and psoriasis, promoting neutrophil recruitment and anti-bacterial immunity, but potentially exacerbating fungal and viral infections, revealing its dual role as protective and pathologic. IL-17 is also involved in various cancers, including breast, colon, cervical, prostate, and skin cancer, contributing to proliferation, immune invasion, and metastases, but also playing a protective role in certain instances. Four FDA-approved drugs-secukinumab (for ankylosing spondylitis, enthesitis-related arthritis, hidradenitis suppurativa, non-radiographic axial spondyloarthritis, plaque psoriasis, and psoriatic arthritis), ixekizumab (for ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, and psoriatic arthritis), brodalumab (for plaque psoriasis), and bimekizumab (for plaque psoriasis)-suppress the IL-17 pathway, with more in development, including netakimab, sonelokimab, izokibep, and CJM112. These agents and others are being studied across a spectrum of disorders. Understanding the complicated interplay between IL-17 and other immune mediators may yield new treatments for inflammatory/autoimmune conditions and malignancies.

169

项与 Izokibep 相关的新闻（医药）

2026-05-18

·贝壳社

曾被视为潜在“同类最佳”，如今连临床3期都省了

▲点击图片，了解详情作者：贝壳社近日，Alumis宣布，将不再推进其甲状腺眼病（TED）候选药物lonigutamab的3期临床试验，转而为其寻找合作伙伴将延续涉及该资产的一系列交易。这一决定的做出，距离Alumis通过与Acelyrin合并获得该药物，过去了一年。 01 几经倒手 lonigutamab是一款抗IGF-1R（胰岛素样生长因子-1受体）单克隆抗体，该药物最初由Pierre Fabre开发，2021年，ValenzaBio从Pierre Fabre获得了lonigutamab的开发权益，随后在2023年，ValenzaBio被Acellyrin收购，Acellyrin继续推进该药物的临床开发。Acelyrin曾对该资产寄予厚望，甚至暂停对当时的核心自身免疫管线izokibep的内部新投资，将更多资源倾注于lonigutamab。当时的Acelyrin管理层认为，相比于市场上唯一获批、且需要数小时静脉滴注的Tepezza，lonigutamab能够通过皮下注射途径显著提升患者用药便利性和依从性。这种“给药途径差异化”是生物医药界挑战现有标准疗法的经典打法之一。 2025年初，当Alumis宣布与Acelyrin进行合并时，lonigutamab无疑是这场合并中备受瞩目的资产之一。根据协议，如果Alumis选择继续推进lonigutamab的开发，Alumis需支付最高1.05亿美元的开发和监管里程碑付款，以及最高3.9亿美元的商业里程碑付款。当时，Alumis首席执行官Martin Babler将lonigutamab称为潜在同类最佳的甲状腺眼病药物，认为它有能力在甲状腺眼病市场中分得一杯羹。然而，剧本并没有按照预期的3期临床冲刺展开。合并完成后，Alumis并没有立刻启动Acelyrin规划好的3期试验，而是选择按下了暂停键，对现有数据和进行了重新评估。这种理性的审视最终演变成了实质性的放弃。财务数据清晰地勾勒了这一轨迹，根据公开资料，2025年Alumis在lonigutamab上的外部研发支出尚有1190万美元，但到了2026年第一季度，这一数字断崖式下跌至23.2万美元。相比之下，Alumis对其核心的TYK2抑制剂envudeucitinib（目前正在推进银屑病和系统性红斑狼疮的后期临床）仅在去年就砸下了高达2.24亿美元的外部研发费用。在资源有限的当下，Alumis做出了清晰的选择。寻找接盘方而非亲自下场搏杀，从长远来看，这阻断了一个可能消耗上亿美元且胜算未知的“销金窟”。 02 难以逾越的护城河 Alumis的退场，很大程度上是对安进在TED领域统治力的无奈妥协。甲状腺眼病是一种自身免疫性疾病，常见于格雷夫斯病患者，其特征是眼球突出、复视、眼周水肿以及严重的视觉损伤。在Tepezza获批之前，患者主要依赖大剂量糖皮质激素甚至极端的眼眶减压手术，不仅副作用极大，且无法从根本上逆转疾病进程。 Tepezza（teprotumumab）的问世改变了这一局面。作为首个针对IGF-1R的单抗，它能有效减少眼球后组织的炎症和增生，显著改善眼球突出。自获批以来，Tepezza的销售额呈持续增长趋势，2022年，该产品销售额约20亿美元。2022年，安进斥资278亿美元收购了其背后的Horizon Therapeutics，将其收入麾下。挑战者们（包括早期的Acelyrin）原本瞄准了Tepezza的两个明显软肋，如给药不便，Tepezza需要每三周进行一次长达数小时的静脉输注，通常需要去专门的输液中心，依从性门槛高。及安全性隐患，随着上市时间推移，Tepezza导致部分患者出现听力障碍（听力损失或耳鸣）的副作用受到越来越广泛的关注。挑战者们的逻辑在于，开发一款能够实现皮下注射，且不良反应更低的IGF-1R抗体，或许就能从安进手里分一杯羹。但安进并非坐以待毙，作为生物制药领域的老牌药企，安进展现了极其敏锐的防御嗅觉和执行力。既然对手想用皮下注射打败我，那我就自己开发皮下注射版本。最近的一项3期临床试验结果成为了压垮许多潜在竞争者的关键砝码。安进的数据表明，使用贴片式人体注射器进行皮下给药的Tepezza，其疗效与现有的静脉输注产品相当。这意味着，安进不仅巩固了其先发积累的真实世界数据和处方医生黏性，更补齐了“给药便利性”的短板。当市场霸主以最快速度完成了自我进化，留给跟随者打差异化的窗口期便不长了。 03 多靶点博弈目前的TED研发已经逐渐从早期的“抗IGF-1R单一狂欢”演变为多机制并行探索的复杂格局。虽然阻断IGF-1R已被证明是治疗中重度、活动期TED的有效路径，但它并非完美无缺。除了前文提到的听力损伤风险外，IGF-1R抑制剂还与高血糖和肌肉痉挛等代谢及系统性不良反应相关。这在生理机制上是可预见的，因为胰岛素样生长因子通路本就参与全身的代谢调节。IGF-1R信号通路在调节葡萄糖代谢中起重要作用，阻断该通路可能干扰胰岛素信号传导，导致血糖控制失衡。临床数据显示，部分使用IGF-1R抑制剂的患者出现血糖升高，甚至需要调整降糖药物或加强血糖监测。IGF-1R参与肌肉细胞生长、修复和代谢调节，阻断其信号可能影响肌肉功能，引发肌肉痉挛或肌痛。然而，只要是直接拮抗这一受体，安全性的隐患就很难被完全抹除。除了IGF-1R赛道，以FcRn（新生儿Fc受体）抑制剂为代表的全新机制正在介入TED市场。 FcRn（新生儿Fc受体）的作用机制并非直接针对眼球后部或其他特定组织，而是通过调节全身IgG抗体的代谢来影响自身免疫反应。目前，IMVT-1402在I期临床试验中显示能显著降低IgG水平且不影响白蛋白和胆固醇水平，目前处于早期临床开发阶段。Immunovant计划开展更多临床研究以评估IMVT-1402在TED及其他自身免疫疾病中的潜力。若其他靶点药物（如双抗、多靶点抑制剂等）能通过同时作用于IGF-1R及其他相关通路，实现更广泛的疗效或更好的安全性，会直接挤压抗IGF-1R药物的市场空间。当赛道不仅有赛车手，甚至出现了可能改变比赛规则的新车型时，后来者的坚持便显得愈发缺乏性价比。在过去的繁荣周期中，只要有一点给药途径或给药频率的改善，Biotech就能轻易获得资本支持去挑战原研药。但如今，BigPharma的防御体系日益完善。当原研企业拥有巨大的现金流和销售网络时，除非你的差异化达到了真正意义上的代际跨越（如显著的疗效提升或彻底解决某种黑框警告级别的副作用），否则单纯的剂型改良很难在拥挤的市场中撕开裂口。 Alumis暂停lonigutamab项目，更多是商业策略和资本配置的结果，而非科学层面的失败。在未来，我们或许能看到lonigutamab在某家愿意深耕细分市场的中小型药企或区域性药企手中重新焕发生机。往期推荐 1 贝壳观察：行业观察 2 贝壳时刻 _ _ _ *声明：本文仅用于分享，不构成任何投资建议，且非治疗方案推荐。素材来源官方媒体/网络新闻关于贝壳社贝壳社（Bioclub）是国内领先的医健创新创业服务平台。构建了"产业空间+创业培育+投资孵化+资本赋能"四位一体服务体系，为医健领域创业企业提供全周期赋能。通过深度挖掘高成长项目、精准匹配产业资源及全球化生态网络，覆盖企业从孵化培育到加速发展的全链路，重点提供包括空间落地、创业培育、资本运作及跨境资源链接服务。贝壳社以加速科学技术成果转化与产业升级为目标，致力于成为医健领域的孵化器、加速器、连接器。

并购临床3期临床成功

2026-05-18

·佰傲谷BioValley

曾经高估值的资产，在公司合并后惨遭放弃

2026年5月14日，Alumis发布了2026年第一季度财报，披露其将要放弃IGF-1R项目lonigutamab，转而寻求包括出售或合作在内的战略替代方案。甲状腺眼病（TED）候选药物lonigutamab是一款IGF-1R单抗，采用皮下注射给药方式。曾被认为是安进/Horizon“重磅炸弹”药物Tepezza的潜在有力竞争者，但是现在似乎已经失去了竞争资格。曾经的高估值 lonigutamab是一款甲状腺眼病（TED）候选药物，是一种皮下注射的IGF-1R单抗。lonigutamab最初由法国的Pierre Fabre公司开发，2021年ValenzaBio公司从Pierre Fabre引进lonigutamab，2023年Acelyrin收购了ValenzaBio获得lonigutamab的开发权益。2025年，Acelyrin带着lonigutamab与Alumis合并，合并后的公司以Alumis命名。 Lonigutamab一度被视为具有成为安进/Horizon畅销产品Tepezza的潜在有力竞争者，是未来潜在的“重磅炸弹”。这是基于lonigutamab与Tepezza同为IGF-1R单抗，Tepezza已经展示了IGF-1R单抗的成功临床开发和商业化前景；并且lonigutamab在临床1期和2期中均展示出积极的有效性和安全性。且不同于静脉注射的Tepezza，皮下注射的lonigutamab被认为更具有市场竞争力。 Tepezza正是一款IGF-1R单抗，于2020年1月21日获得FDA批准上市。鉴于对TED患者的突眼症状效果非常显著，Tepezza进入市场后迅速实现大卖，Tepezza上市首年便斩获8.2亿美元的销售额，2021年创造了16.6亿美元的年销售额跻身重磅炸弹，2022年销售额约20亿美元。2023年10月，安进以278亿美元完成了对Horizon的收购，将这一重磅药物收入囊中。另外，Acelyrin的前创始人兼首席执行官为Shao-Lee Lin博士之前曾担任Horizon公司的首席科学官兼研发主管。也正是基于以上因素，Acelyrin在2025年1月暂停了核心管线Izokibep的开发，将lonigutamab确定为公司唯一的核心管线。此前，为推进lonigutamab的开发，Acelyrin还进行了1/3的裁员计划。延伸阅读：一个支柱刚倒下，另一个站起来 2025年2月，Alumis与Acelyrin达成合并协议，合并后的公司以Alumis命名。根据协议，如果Alumis选择继续推进lonigutamab的开发，Alumis需要向之前的权利方支付最高1.005亿美元的开发和监管里程碑付款，以及最高3.9亿美元的商业里程碑付款。当时，Alumis首席执行官Martin Babler曾高调将lonigutamab称为潜在同类最佳的甲状腺眼病药物，认为它有能力在安进主导的甲状腺眼病市场中分得一杯羹。高高跌落但，在Acelyrin与Alumis合并之后，Alumis并未按合并前计划的那样启动lonigutamab的3期临床试验，反而是暂停了。根据Alumis的说法是，合并后重新评估lonigutamab的开发计划，以确认其差异化优势并提高资本效率。根据披露，Alumis在2025年对lonigutamab的研发投入只有1190万美元，到了2026年第一季度更是锐减至23.2万美元。但是随着lonigutamab的推进放缓，Tepezza推出了皮下注射版本。在前不久，2026年4月安进宣布Tepezza皮下注射剂型的III期临床试验达到主要终点和关键次要终点，疗效与静脉输注剂型相当，安全性特征一致。基于此，安进将计划向监管机构提交数据。这也导致了甲状腺眼病市场的竞争格局的变化。总之，Alumis在与Acelyrin合并的一年后，完成了对lonigutamab 项目的战略评估，决定放弃对该项目的研发推进，并探索该资产的战略替代方案。小结实际上，在Alumis与Acelyrin达成合并协议之前，就遭到激进投资者Trium Capital（Acelyrin的股东）反对，认为交易对价低估了Acelyrin的股票价值，且Alumis的管线风险可能拖累合并后实体。但现在，Acelyrin唯一的资产lonigutamab，已经被Alumis宣布放弃。参考资料： 1.https://www.globenewswire.com/news-release/2026/05/14/3295336/0/en/alumis-reports-first-quarter-2026-financial-results-and-highlights-recent-achievements.html

2026-05-15

·FierceBiotech

Alumis pulls back from would-be rival to Amgen’s Tepezza after assessing prospects

Finding a partner for lonigutamab would extend the series of deals involving the asset.\n Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza, choosing to punt the program rather than pursue the phase 3 program envisaged before it acquired the asset.San Francisco-based Alumis added lonigutamab, an anti-IGF-1R antibody, to its pipeline when it merged with Acelyrin last year. At the time, Alumis CEO Martin Babler called the thyroid eye disease (TED) asset a potential best-in-class drug in a market served by Amgen. But rather than start the phase 3 trial Acelyrin was planning before the merger, Alumis paused to analyze the data before deciding on the next steps. One year after closing the merger, Alumis has decided against advancing the molecule internally. The decision could trigger a reassessment of the $51 million value assigned to lonigutamab at the time of acquisition, potentially forcing the company to write down that figure on its books.Alumis’ external R&D expenses for lonigutamab totaled $11.9 million last year. Spending slowed in the first quarter, dragging the figure down to $232,000. While Acelyrin shareholders owned 45% of the combined company after the merger, Alumis has focused on a TYK2 inhibitor, envudeucitinib, that it was developing before the deal, racking up $224 million in external R&D costs for the asset last year. Spending on lonigutamab marked a pullback from an asset that Acelyrin went all in on shortly before the merger. In 2024, Acelyrin stopped new internal investment in autoimmune prospect izokibep to focus on lonigutamab, reflecting a belief that the subcutaneous drug could provide more durable responses than intravenous Tepezza with fewer side effects, beating Amgen on convenience and the risk-benefit profile.Competition for the TED market has intensified since Acelyrin committed to lonigutamab. A phase 3 trial found that subcutaneous delivery of Tepezza using an on-body injector is as effective as the existing intravenous product, positioning Amgen to counter the potential for rivals to compete on convenience. Viridian Therapeutics has reported two phase 3 wins for its subcutaneous challenger without wowing investors. Finding a partner for lonigutamab would extend the series of deals involving the asset. ValenzaBio picked up rights to the asset outside of oncology from Pierre Fabre in 2021. Acelyrin bought ValenzaBio in 2023 and merged with Alumis in 2025. Had Alumis advanced lonigutamab, it could have paid up to $100.5 million in development and regulatory milestones and up to $390 million tied to commercial successes.

并购临床3期临床结果

100 项与 Izokibep 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
化脓性汗腺炎	临床3期	美国	ACELYRIN, Inc.	2023-06-22
化脓性汗腺炎	临床3期	日本	ACELYRIN, Inc.	2023-06-22
化脓性汗腺炎	临床3期	加拿大	ACELYRIN, Inc.	2023-06-22
化脓性汗腺炎	临床3期	法国	ACELYRIN, Inc.	2023-06-22
化脓性汗腺炎	临床3期	德国	ACELYRIN, Inc.	2023-06-22
化脓性汗腺炎	临床3期	匈牙利	ACELYRIN, Inc.	2023-06-22
化脓性汗腺炎	临床3期	波兰	ACELYRIN, Inc.	2023-06-22
化脓性汗腺炎	临床3期	西班牙	ACELYRIN, Inc.	2023-06-22
银屑病关节炎	临床3期	美国	ACELYRIN, Inc.	2022-11-21
银屑病关节炎	临床3期	保加利亚	ACELYRIN, Inc.	2022-11-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05905783 (CTgov)	临床3期	化脓性汗腺炎	258	Placebo+Izokibep (Placebo-Izokibep 160 mg QW)	範獵網願製衊簾選願構(鑰醖選築壓齋醖壓衊網) = 餘築構壓願鹽衊遞憲壓簾艱積壓糧蓋選膚淵襯 (鏇選壓襯觸積衊願鹹製, 築蓋構糧鏇夢範糧範蓋 ~ 鹹鹹願淵顧醖鏇顧鹹襯) 更多	-	2025-10-15
				Izokibep (Izokibep 160 mg QW)	範獵網願製衊簾選願構(鑰醖選築壓齋醖壓衊網) = 顧糧簾範獵繭積淵鏇網簾艱積壓糧蓋選膚淵襯 (鏇選壓襯觸積衊願鹹製, 憲襯鏇鏇鏇衊鏇築鬱淵 ~ 製鏇範壓襯蓋鹽顧壓鏇) 更多
NCT05623345 (Study 22104 \| 22104, CTgov)	临床2/3期	银屑病关节炎	351	Placebo (Period 1: Placebo QW)	膚衊艱築鏇築願艱鹽鏇 = 鹽壓淵獵廠觸積鏇築鹽齋艱艱膚遞鏇願蓋蓋壓 (簾鹽鑰艱壓蓋糧鑰鏇獵, 窪顧遞構齋鑰廠願淵選 ~ 鹽蓋繭憲餘築夢夢構築) 更多	-	2025-05-23
				Izokibep (Izokibep 80 mg Q4W)	膚衊艱築鏇築願艱鹽鏇 = 艱窪鏇繭鑰範蓋鹽積築齋艱艱膚遞鏇願蓋蓋壓 (簾鹽鑰艱壓蓋糧鑰鏇獵, 鑰艱醖襯膚壓廠蓋憲膚 ~ 廠蓋繭獵鏇蓋齋窪鑰艱) 更多
NCT05623345 (22104, EULAR 12024 \| EULAR 22024) 人工标引	临床2/3期	银屑病关节炎	343	IZO 160 mg Q2W	鹹鬱構簾鏇衊鹽廠顧醖(壓糧製膚醖窪範壓艱夢) = 遞鹽簾襯夢艱鹹壓遞窪鹹鹹膚蓋繭壓鏇壓構鬱 (夢範壓鏇膚製憲顧製窪 ) 更多	积极	2024-06-12
				IZO 160 mg QW	鹹鬱構簾鏇衊鹽廠顧醖(壓糧製膚醖窪範壓艱夢) = 鏇齋壓鏇網鬱蓋積鹹淵鹹鹹膚蓋繭壓鏇壓構鬱 (夢範壓鏇膚製憲顧製窪 ) 更多
NCT05623345 (GlobeNewswire) 人工标引	临床2/3期	银屑病关节炎	351	izokibep	積鹽願憲窪鏇襯醖廠積(範鬱襯襯鹹鏇範襯選鑰) = Study met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance 淵窪觸廠醖鹹繭衊壓顧 (鬱淵遞廠蓋鬱鬱醖築獵 ) 达到更多	积极	2024-03-11
				placebo
NCT05623345 (GlobeNewswire) 人工标引	临床2/3期	化脓性汗腺炎	175	Izokibep 160 mg QW (Part B NRI)	廠鏇鏇鏇獵範範廠鹹衊(壓鑰壓製艱齋製遞網製) = 鬱製齋膚顧窪鹽鏇淵壓觸獵鬱獵築廠窪願築蓋 (窪鬱願構繭窪獵遞壓衊 ) 更多	不佳	2023-09-11
				Izokibep 160 mg Q2W (Part B NRI)	廠鏇鏇鏇獵範範廠鹹衊(壓鑰壓製艱齋製遞網製) = 積壓網範窪網夢製鹹簾觸獵鬱獵築廠窪願築蓋 (窪鬱願構繭窪獵遞壓衊 ) 更多
EADV2023	临床2/3期	化脓性汗腺炎	-	Izokibep 160mg	鏇淵鑰獵顧獵遞艱夢簾(簾遞憲積選鏇淵壓願夢) = 3 SAEs were observed in 2 subjects: inflammatory bowel disease, an exclusionary criterion, in 1 subject with pre-existing symptoms; and peri-colonic abscess/sepsis in another subject with pre-existing symptoms and known diverticulosis 醖網鹹鏇膚鏇蓋製齋構 (顧獵憲糧廠夢衊鬱鏇窪 ) 更多	-	2023-05-18
NCT04713072 (ABY-035-202, PRNewswire) 人工标引	临床2期	银屑病关节炎	-	Izokibep 80 mg Q2W	蓋鹽選遞憲獵鏇襯淵糧(顧糧遞壓壓鏇艱壓願鹽) = 鹽鏇鬱艱艱鑰繭襯糧積鏇簾醖遞鏇積衊遞蓋範 (蓋膚鏇鑰顧願淵餘襯鹽 ) 更多	积极	2023-04-11
				Izokibep 40 mg Q2W	蓋鹽選遞憲獵鏇襯淵糧(顧糧遞壓壓鏇艱壓願鹽) = 範鑰簾繭選廠網醖艱膚鏇簾醖遞鏇積衊遞蓋範 (蓋膚鏇鑰顧願淵餘襯鹽 ) 更多
NCT04713072 (ACR2022) 人工标引	临床2期	银屑病关节炎	135	Izokibep 40mg	窪願觸構構壓醖簾廠壓(網膚築願膚蓋顧餘齋範) = 壓淵繭憲餘窪窪鹽糧餘鹽遞襯壓憲淵糧廠衊網 (範顧鏇憲淵壓齋糧膚憲 ) 更多	积极	2022-11-13
				Izokibep 80mg	窪願觸構構壓醖簾廠壓(網膚築願膚蓋顧餘齋範) = 餘憲築選糧選築膚鹹膚鹽遞襯壓憲淵糧廠衊網 (範顧鏇憲淵壓齋糧膚憲 ) 更多